Novartis in the lead to acquire cancer drug developer MorphoSys
Reuters
Reuters exclusively reported that drug maker Novartis AG (NOVN.S) is in advanced talks to acquire MorphoSys AG (MORG.DE), a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion).
The post Novartis in the lead to acquire cancer drug developer MorphoSys appeared first on Reuters News Agency.